Ranibizumab

Indication

Choroidal neovascularisation (pathological myopia) NICE TA298

NICE TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

Red

Brand:

Lucentis®

Nice TA:

298

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

Background

Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme. Ranibizumab is an alternative treatment option to verteporfin photodynamic therapy (vPDT).

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Pending	Red	Red	Pending	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - Dec - 2013